Open AccessReview
Antitumor Virotherapy by Attenuated Measles Virus (MV)
by
Jean-Baptiste Guillerme 1,2,3, Marc Gregoire 1,2,3, Frédéric Tangy 4 and Jean-François Fonteneau 1,2,3,*
1
INSERM, UMR892, Nantes, F-44000, France
2
CNRS, UMR6299, Nantes, F-44000, France
3
Université de Nantes, Nantes, F-44000, France
4
CNRS, URA3015, Institut Pasteur, Unité de Génomique Virale et Vaccination, Paris, 75015, France
Cited by 15 | Viewed by 7374
Abstract
Antitumor virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. Vaccine-attenuated strains of measles virus (MV) are good candidates for this approach. Attenuated MV uses the CD46 molecule as a major entry receptor
[...] Read more.
Antitumor virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. Vaccine-attenuated strains of measles virus (MV) are good candidates for this approach. Attenuated MV uses the CD46 molecule as a major entry receptor into cells. This molecule negatively regulates the complement system and is frequently overexpressed by cancer cells to escape lysis by the complement system. MV exhibits oncolytic properties in many cancer types
in vitro, and in mouse models. Phase I clinical trials using MV are currently underway. Here, we review the state of this therapeutic approach, with a focus on the effects of MV on the antitumor immune response.
Full article